{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Cdc-25A", "PTP-1B", "Penicillium chrysogenum", "Red Sea fungi", "anticancer activity", "c-Met kinase", "drug-likeness/pharmacokinetic profiling", "indole-based alkaloids", "molecular modelling"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36837781", "DateRevised": {"Year": "2023", "Month": "03", "Day": "01"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "01", "Day": "21"}], "Language": ["eng"], "ELocationID": ["162", "10.3390/metabo13020162"], "Journal": {"ISSN": "2218-1989", "JournalIssue": {"Volume": "13", "Issue": "2", "PubDate": {"Year": "2023", "Month": "Jan", "Day": "21"}}, "Title": "Metabolites", "ISOAbbreviation": "Metabolites"}, "ArticleTitle": "Molecular and Biological Investigation of Isolated Marine Fungal Metabolites as Anticancer Agents: A Multi-Target Approach.", "Abstract": {"AbstractText": ["Cancer is the leading cause of death globally, with an increasing number of cases being annually reported. Nature-derived metabolites have been widely studied for their potential programmed necrosis, cytotoxicity, and anti-proliferation leading to enrichment for the modern medicine, particularly within the last couple of decades. At a more rapid pace, the concept of multi-target agents has evolved from being an innovative approach into a regular drug development procedure for hampering the multi-fashioned pathophysiology and high-resistance nature of cancer cells. With the advent of the Red Sea <i>Penicillium chrysogenum</i> strain S003-isolated indole-based alkaloids, we thoroughly investigated the molecular aspects for three major metabolites: meleagrin (MEL), roquefortine C (ROC), and isoroquefortine C (ISO) against three cancer-associated biological targets Cdc-25A, PTP-1B, and c-Met kinase. The study presented, for the first time, the detailed molecular insights and near-physiological affinity for these marine indole alkaloids against the assign targets through molecular docking-coupled all-atom dynamic simulation analysis. Findings highlighted the superiority of MEL's binding affinity/stability being quite in concordance with the in vitro anticancer activity profile conducted via sulforhodamine B bioassay on different cancerous cell lines reaching down to low micromolar or even nanomolar potencies. The advent of lengthy structural topologies via the metabolites' extended tetracyclic cores and aromatic imidazole arm permitted multi-pocket accommodation addressing the selectivity concerns. Additionally, the presence decorating polar functionalities on the core hydrophobic tetracyclic ring contributed compound's pharmacodynamic preferentiality. Introducing ionizable functionality with more lipophilic characters was highlighted to improve binding affinities which was also in concordance with the conducted drug-likeness/pharmacokinetic profiling for obtaining a balanced pharmacokinetic/dynamic profile. Our study adds to the knowledge regarding drug development and optimization of marine-isolated indole-based alkaloids for future iterative synthesis and pre-clinical investigations as multi-target anticancer agents."]}, "AuthorList": [{"Identifier": ["0000-0001-5974-6235"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia."}], "LastName": "Bogari", "ForeName": "Hanin A", "Initials": "HA"}, {"Identifier": ["0000-0003-3799-0581"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Natural Products, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia."}], "LastName": "Elhady", "ForeName": "Sameh S", "Initials": "SS"}, {"Identifier": ["0000-0002-0597-482X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicinal Chemistry, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt."}], "LastName": "Darwish", "ForeName": "Khaled M", "Initials": "KM"}, {"Identifier": ["0000-0003-3879-104X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy, Faculty of Pharmacy, University of Sadat City, Sadat City 32897, Egypt."}], "LastName": "Refaey", "ForeName": "Mohamed S", "Initials": "MS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Aquaculture, Faculty of Aquatic and Fisheries Sciences, Kafrelsheikh University, Kafrelsheikh 33516, Egypt."}], "LastName": "Mohamed", "ForeName": "Radi A", "Initials": "RA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy, Faculty of Pharmacy, Galala University, New Galala 43713, Egypt."}, {"Identifier": [], "Affiliation": "Department of Pharmacognosy, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt."}], "LastName": "Abdelhameed", "ForeName": "Reda F A", "Initials": "RFA"}, {"Identifier": ["0000-0002-1333-980X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia."}], "LastName": "Almalki", "ForeName": "Ahmad J", "Initials": "AJ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Pharmacy, College of Pharmacy, Umm Al-Qura University, P.O. Box 13578, Makkah 21955, Saudi Arabia."}], "LastName": "Aldurdunji", "ForeName": "Mohammed M", "Initials": "MM"}, {"Identifier": ["0000-0001-8817-6243"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia."}], "LastName": "Lashkar", "ForeName": "Manar O", "Initials": "MO"}, {"Identifier": ["0000-0002-3668-4905"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia."}], "LastName": "Alshehri", "ForeName": "Samah O", "Initials": "SO"}, {"Identifier": ["0000-0002-0208-1612"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia."}], "LastName": "Malatani", "ForeName": "Rania T", "Initials": "RT"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Garden for Medicinal Plants, Graduate School of Biomedical Sciences, Nagasaki University, Bunkyo-machi 1-14, Nagasaki 852-8521, Japan."}], "LastName": "Yamada", "ForeName": "Koji", "Initials": "K"}, {"Identifier": ["0000-0002-7658-4618"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy, Faculty of Pharmacy, Port Said University, Port Said 42526, Egypt."}], "LastName": "Khedr", "ForeName": "Amgad I M", "Initials": "AIM"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Metabolites", "NlmUniqueID": "101578790", "ISSNLinking": "2218-1989"}, "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Uzma F., Mohan C.D., Hashem A., Konappa N.M., Rangappa S., Kamath P.V., Singh B.P., Mudili V., Gupta V.K., Siddaiah C.N. Endophytic fungi\u2014Alternative sources of cytotoxic compounds: A review. Front. Pharmacol. 2018;9:309. doi: 10.3389/fphar.2018.00309.", "ArticleIdList": ["10.3389/fphar.2018.00309", "PMC5932204", "29755344"]}, {"Citation": "WHO  WHO FactSheets: Cancer.  [(accessed on 15 May 2022)].  Available online:  https://www.who.int/news-room/fact-sheets/detail/cancer."}, {"Citation": "Chavda V.P. Chapter 4-Nanobased Nano Drug Delivery: A Comprehensive Review. In: Mohapatra S.S., Ranjan S., Dasgupta N., Mishra R.K., Thomas S., editors. Applications of Targeted Nano Drugs and Delivery Systems. Elsevier; Amsterdam, The Netherlands: 2019. pp. 69\u201392.", "ArticleIdList": ["10.1016/B978-0-12-814029-1.00004-1"]}, {"Citation": "Chavda V.P., Ertas Y.N., Walhekar V., Modh D., Doshi A., Shah N., Anand K., Chhabria M. Advanced Computational Methodologies Used in the Discovery of New Natural Anticancer Compounds. Front. Pharmacol. 2021;12:702611. doi: 10.3389/fphar.2021.702611.", "ArticleIdList": ["10.3389/fphar.2021.702611", "PMC8416109", "34483905"]}, {"Citation": "Tran G., Zafar S.Y. Financial toxicity and implications for cancer care in the era of molecular and immune therapies. Ann. Transl. Med. 2018;6:166. doi: 10.21037/atm.2018.03.28.", "ArticleIdList": ["10.21037/atm.2018.03.28", "PMC5985271", "29911114"]}, {"Citation": "Ramsay R.R., Popovic-Nikolic M.R., Nikolic K., Uliassi E., Bolognesi M.L. A perspective on multi-target drug discovery and design for complex diseases. Clin. Transl. Med. 2018;7:3. doi: 10.1186/s40169-017-0181-2.", "ArticleIdList": ["10.1186/s40169-017-0181-2", "PMC5770353", "29340951"]}, {"Citation": "Genovese M., Imperatore C., Casertano M., Aiello A., Balestri F., Piazza L., Menna M., Del Corso A., Paoli P. Dual Targeting of PTP1B and Aldose Reductase with Marine Drug Phosphoeleganin: A Promising Strategy for Treatment of Type 2 Diabetes. Mar. Drugs. 2021;19:535. doi: 10.3390/md19100535.", "ArticleIdList": ["10.3390/md19100535", "PMC8540617", "34677434"]}, {"Citation": "Adnane L., Trail P.A., Taylor I., Wilhelm S.M. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2006;407:597\u2013612. doi: 10.1016/s0076-6879(05)07047-3.", "ArticleIdList": ["10.1016/s0076-6879(05)07047-3", "16757355"]}, {"Citation": "Remesh A. Toxicities of Anticancer Drugs and Its Management. Int. J. Basic Clin. Pharmacol. 2012;1:2\u201312. doi: 10.5455/2319-2003.ijbcp000812.", "ArticleIdList": ["10.5455/2319-2003.ijbcp000812"]}, {"Citation": "Kumar M.S., Adki K.M. Marine natural products for multi-targeted cancer treatment: A future insight. Biomed. Pharmacother. 2018;105:233\u2013245. doi: 10.1016/j.biopha.2018.05.142.", "ArticleIdList": ["10.1016/j.biopha.2018.05.142", "29859466"]}, {"Citation": "Taylor W.F., Moghadam S.E., Moridi Farimani M., Ebrahimi S.N., Tabefam M., Jabbarzadeh E. A multi-targeting natural compound with growth inhibitory and anti-angiogenic properties re-sensitizes chemotherapy resistant cancer. PLoS ONE. 2019;14:e0218125. doi: 10.1371/journal.pone.0218125.", "ArticleIdList": ["10.1371/journal.pone.0218125", "PMC6559640", "31185048"]}, {"Citation": "Schulz B., Boyle C., Draeger S., R\u00f6mmert A.-K., Krohn K. Endophytic fungi: A source of novel biologically active secondary metabolites. Mycol. Res. 2002;106:996\u20131004. doi: 10.1017/S0953756202006342.", "ArticleIdList": ["10.1017/S0953756202006342"]}, {"Citation": "Rateb M.E., Ebel R. Secondary metabolites of fungi from marine habitats. Nat. Prod. Rep. 2011;28:290\u2013344. doi: 10.1039/c0np00061b.", "ArticleIdList": ["10.1039/c0np00061b", "21229157"]}, {"Citation": "Mady M., Haggag E. Review on Fungi of Genus Penicillium As a Producers of Biologically Active Polyketides. J. Adv. Pharm. Res. 2020;4:33\u201345. doi: 10.21608/aprh.2020.25896.1100.", "ArticleIdList": ["10.21608/aprh.2020.25896.1100"]}, {"Citation": "Sun J., Zhu Z.-X., Song Y.-L., Dong D., Zheng J., Liu T., Zhao Y.-F., Ferreira D., Zjawiony J.K., Tu P.-F. Nitric oxide inhibitory meroterpenoids from the fungus Penicillium purpurogenum MHZ 111. J. Nat. Prod. 2016;79:1415\u20131422. doi: 10.1021/acs.jnatprod.6b00160.", "ArticleIdList": ["10.1021/acs.jnatprod.6b00160", "27120704"]}, {"Citation": "Samson R., Houbraken J., Thrane U., Frisvad J., Andersen B. Food and Indoor Fungi, CBS Laboratory Manual Series 2. CBS-Fungal Biodiversity Centre; Utrecht, The Netherlands: 2010."}, {"Citation": "Song Q.-Y., Cheng F.-S., Sun M., Gao K., Nan Z.-B. Metabolites from Epichlo\u00eb bromicola Obtained by Co-Culture with Pestalotiopsis microspore as Inhibitors of Cdc25A Phosphatases, Plant Pathogens, and Grasses. Chem. Nat. Compd. 2021;57:382\u2013384. doi: 10.1007/s10600-021-03364-4.", "ArticleIdList": ["10.1007/s10600-021-03364-4"]}, {"Citation": "Han W., Cai J., Zhong W., Xu G., Wang F., Tian X., Zhou X., Liu Q., Liu Y., Wang J. Protein tyrosine phosphatase 1B (PTP1B) inhibitorsfrom the deep-sea fungus Penicillium chrysogenum SCSIO 07007. Bioorg. Chem. 2020;96:103646. doi: 10.1016/j.bioorg.2020.103646.", "ArticleIdList": ["10.1016/j.bioorg.2020.103646", "32036160"]}, {"Citation": "Fauman E.B., Cogswell J.P., Lovejoy B., Rocque W.J., Holmes W., Montana V.G., Piwnica-Worms H., Rink M.J., Saper M.A. Crystal structure of the catalytic domain of the human cell cycle control phosphatase, Cdc25A. Cell. 1998;93:617\u2013625. doi: 10.1016/S0092-8674(00)81190-3.", "ArticleIdList": ["10.1016/S0092-8674(00)81190-3", "9604936"]}, {"Citation": "Sur S., Agrawal D.K. Phosphatases and kinases regulating CDC25 activity in the cell cycle: Clinical implications of CDC25 overexpression and potential treatment strategies. Mol. Cell. Biochem. 2016;416:33\u201346. doi: 10.1007/s11010-016-2693-2.", "ArticleIdList": ["10.1007/s11010-016-2693-2", "PMC4862931", "27038604"]}, {"Citation": "Boutros R., Lobjois V., Ducommun B. CDC25 phosphatases in cancer cells: Key players? Good targets? Nat. Rev. Cancer. 2007;7:495\u2013507. doi: 10.1038/nrc2169.", "ArticleIdList": ["10.1038/nrc2169", "17568790"]}, {"Citation": "Zhang Z., Zhang G., Kong C. High expression of Cdc25B and low expression of 14-3-3\u03c3 is associated with the development and poor prognosis in urothelial carcinoma of bladder. Tumor Biol. 2014;35:2503\u20132512. doi: 10.1007/s13277-013-1331-9.", "ArticleIdList": ["10.1007/s13277-013-1331-9", "24234332"]}, {"Citation": "Julien S.G., Dub\u00e9 N., Read M., Penney J., Paquet M., Han Y., Kennedy B.P., Muller W.J., Tremblay M.L. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis. Nat. Genet. 2007;39:338\u2013346. doi: 10.1038/ng1963.", "ArticleIdList": ["10.1038/ng1963", "17259984"]}, {"Citation": "Bentires-Alj M., Neel B.G. Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer. Cancer Res. 2007;67:2420\u20132424. doi: 10.1158/0008-5472.CAN-06-4610.", "ArticleIdList": ["10.1158/0008-5472.CAN-06-4610", "17347513"]}, {"Citation": "Zhu S., Bjorge J.D., Fujita D.J. PTP1B contributes to the oncogenic properties of colon cancer cells through Src activation. Cancer Res. 2007;67:10129\u201310137. doi: 10.1158/0008-5472.CAN-06-4338.", "ArticleIdList": ["10.1158/0008-5472.CAN-06-4338", "17974954"]}, {"Citation": "Cortesio C.L., Chan K.T., Perrin B.J., Burton N.O., Zhang S., Zhang Z.Y., Huttenlocher A. Calpain 2 and PTP1B function in a novel pathway with Src to regulate invadopodia dynamics and breast cancer cell invasion. J. Cell Biol. 2008;180:957\u2013971. doi: 10.1083/jcb.200708048.", "ArticleIdList": ["10.1083/jcb.200708048", "PMC2265405", "18332219"]}, {"Citation": "Zhang Z.Y. Protein tyrosine phosphatases: Structure and function, substrate specificity, and inhibitor development. Annu. Rev. Pharmacol. Toxicol. 2002;42:209\u2013234. doi: 10.1146/annurev.pharmtox.42.083001.144616.", "ArticleIdList": ["10.1146/annurev.pharmtox.42.083001.144616", "11807171"]}, {"Citation": "Liu G. Protein tyrosine phosphatase 1B inhibition: Opportunities and challenges. Curr. Med. Chem. 2003;10:1407\u20131421. doi: 10.2174/0929867033457296.", "ArticleIdList": ["10.2174/0929867033457296", "12871138"]}, {"Citation": "Puius Y.A., Zhao Y., Sullivan M., Lawrence D.S., Almo S.C., Zhang Z.Y. Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: A paradigm for inhibitor design. Proc. Natl. Acad. Sci. USA. 1997;94:13420\u201313425. doi: 10.1073/pnas.94.25.13420.", "ArticleIdList": ["10.1073/pnas.94.25.13420", "PMC28320", "9391040"]}, {"Citation": "Zhang S., Zhang Z.Y. PTP1B as a drug target: Recent developments in PTP1B inhibitor discovery. Drug Discov. Today. 2007;12:373\u2013381. doi: 10.1016/j.drudis.2007.03.011.", "ArticleIdList": ["10.1016/j.drudis.2007.03.011", "17467573"]}, {"Citation": "Mady M.S., Mohyeldin M.M., Ebrahim H.Y., Elsayed H.E., Houssen W.E., Haggag E.G., Soliman R.F., El Sayed K.A. The indole alkaloid meleagrin, from the olive tree endophytic fungus Penicillium chrysogenum, as a novel lead for the control of c-Met-dependent breast cancer proliferation, migration and invasion. Bioorg. Med. Chem. 2016;24:113\u2013122. doi: 10.1016/j.bmc.2015.11.038.", "ArticleIdList": ["10.1016/j.bmc.2015.11.038", "PMC4703546", "26692349"]}, {"Citation": "Gherardi E., Birchmeier W., Birchmeier C., Vande Woude G. Targeting MET in cancer: Rationale and progress. Nat. Rev. Cancer. 2012;12:89\u2013103. doi: 10.1038/nrc3205.", "ArticleIdList": ["10.1038/nrc3205", "22270953"]}, {"Citation": "Birchmeier C., Birchmeier W., Gherardi E., Vande Woude G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 2003;4:915\u2013925. doi: 10.1038/nrm1261.", "ArticleIdList": ["10.1038/nrm1261", "14685170"]}, {"Citation": "Boccaccio C., Comoglio P.M. Invasive growth: A MET-driven genetic programme for cancer and stem cells. Nat. Rev. Cancer. 2006;6:637\u2013645. doi: 10.1038/nrc1912.", "ArticleIdList": ["10.1038/nrc1912", "16862193"]}, {"Citation": "Ma P.C., Tretiakova M.S., MacKinnon A.C., Ramnath N., Johnson C., Dietrich S., Seiwert T., Christensen J.G., Jagadeeswaran R., Krausz T., et al. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer. 2008;47:1025\u20131037. doi: 10.1002/gcc.20604.", "ArticleIdList": ["10.1002/gcc.20604", "PMC2583960", "18709663"]}, {"Citation": "Cui J.J. Targeting receptor tyrosine kinase MET in cancer: Small molecule inhibitors and clinical progress. J. Med. Chem. 2014;57:4427\u20134453. doi: 10.1021/jm401427c.", "ArticleIdList": ["10.1021/jm401427c", "24320965"]}, {"Citation": "Furlan A., Kherrouche Z., Montagne R., Copin M.C., Tulasne D. Thirty years of research on met receptor to move a biomarker from bench to bedside. Cancer Res. 2014;74:6737\u20136744. doi: 10.1158/0008-5472.CAN-14-1932.", "ArticleIdList": ["10.1158/0008-5472.CAN-14-1932", "25411347"]}, {"Citation": "Peters S., Adjei A.A. MET: A promising anticancer therapeutic target. Nat. Rev. Clin. Oncol. 2012;9:314\u2013326. doi: 10.1038/nrclinonc.2012.71.", "ArticleIdList": ["10.1038/nrclinonc.2012.71", "22566105"]}, {"Citation": "Gimeno A., Ojeda-Montes M.J., Tom\u00e1s-Hern\u00e1ndez S., Cereto-Massagu\u00e9 A., Beltr\u00e1n-Deb\u00f3n R., Mulero M., Pujadas G., Garcia-Vallv\u00e9 S. The Light and Dark Sides of Virtual Screening: What Is There to Know? Int. J. Mol. Sci. 2019;20:1375. doi: 10.3390/ijms20061375.", "ArticleIdList": ["10.3390/ijms20061375", "PMC6470506", "30893780"]}, {"Citation": "Asfour H.Z., Awan Z.A., Bagalagel A.A., Elfaky M.A., Abdelhameed R.F.A., Elhady S.S. Large-Scale Production of Bioactive Terrein by Aspergillus terreus Strain S020 Isolated from the Saudi Coast of the Red Sea. Biomolecules. 2019;9:480. doi: 10.3390/biom9090480.", "ArticleIdList": ["10.3390/biom9090480", "PMC6769563", "31547354"]}, {"Citation": "Alahdal A.M., Asfour H.Z., Ahmed S.A., Noor A.O., Al-Abd A.M., Elfaky M.A., Elhady S.S. Anti-Helicobacter, Antitubercular and Cytotoxic Activities of Scalaranes from the Red Sea Sponge Hyrtios erectus. Molecules. 2018;23:978. doi: 10.3390/molecules23040978.", "ArticleIdList": ["10.3390/molecules23040978", "PMC6017761", "29690588"]}, {"Citation": "Papazisis K.T., Geromichalos G.D., Dimitriadis K.A., Kortsaris A.H. Optimization of the sulforhodamine B colorimetric assay. J. Immunol. Methods. 1997;208:151\u2013158. doi: 10.1016/S0022-1759(97)00137-3.", "ArticleIdList": ["10.1016/S0022-1759(97)00137-3", "9433470"]}, {"Citation": "Eberhardt J., Santos-Martins D., Tillack A.F., Forli S. AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings. J. Chem. Inf. Model. 2021;61:3891\u20133898. doi: 10.1021/acs.jcim.1c00203.", "ArticleIdList": ["10.1021/acs.jcim.1c00203", "34278794"]}, {"Citation": "Trott O., Olson A.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010;31:455\u2013461. doi: 10.1002/jcc.21334.", "ArticleIdList": ["10.1002/jcc.21334", "PMC3041641", "19499576"]}, {"Citation": "Xue Q., Liu X., Russell P., Li J., Pan W., Fu J., Zhang A. Evaluation of the binding performance of flavonoids to estrogen receptor alpha by Autodock, Autodock Vina and Surflex-Dock. Ecotoxicol. Environ. Saf. 2022;233:113323. doi: 10.1016/j.ecoenv.2022.113323.", "ArticleIdList": ["10.1016/j.ecoenv.2022.113323", "35183811"]}, {"Citation": "Schr\u00f6dinger, LLC . The PyMOL Molecular Graphics System. Schr\u00f6dinger LLC; New York, NY, USA: 2016. Version 2.0.6."}, {"Citation": "Elhady S.S., Abdelhameed R.F.A., Malatani R.T., Alahdal A.M., Bogari H.A., Almalki A.J., Mohammad K.A., Ahmed S.A., Khedr A.I.M., Darwish K.M. Molecular Docking and Dynamics Simulation Study of Hyrtios erectus Isolated Scalarane Sesterterpenes as Potential SARS-CoV-2 Dual Target Inhibitors. Biology. 2021;10:389. doi: 10.3390/biology10050389.", "ArticleIdList": ["10.3390/biology10050389", "PMC8147222", "34062724"]}, {"Citation": "P\u00e1ll S., Abraham M.J., Kutzner C., Hess B., Lindahl E. Tackling Exascale Software Challenges in Molecular Dynamics Simulations with GROMACS. In: Markidis S., Laure E., editors. Solving Software Challenges for Exascale. Springer International Publishing; Cham, Switzerland: 2015. pp. 3\u201327."}, {"Citation": "Saleh A.H., Abdelwaly A., Darwish K.M., Eissa A., Chittiboyina A., Helal M.A. Deciphering the molecular basis of the kappa opioid receptor selectivity: A Molecular Dynamics study. J. Mol. Graph. Model. 2021;106:107940. doi: 10.1016/j.jmgm.2021.107940.", "ArticleIdList": ["10.1016/j.jmgm.2021.107940", "34015577"]}, {"Citation": "Ross G.A., Rustenburg A.S., Grinaway P.B., Fass J., Chodera J.D. Biomolecular Simulations under Realistic Macroscopic Salt Conditions. J. Phys. Chem. B. 2018;122:5466\u20135486. doi: 10.1021/acs.jpcb.7b11734.", "ArticleIdList": ["10.1021/acs.jpcb.7b11734", "PMC6078207", "29649876"]}, {"Citation": "Zaki A.A., Ashour A., Elhady S.S., Darwish K.M., Al-Karmalawy A.A. Calendulaglycoside A Showing Potential Activity Against SARS-CoV-2 Main Protease: Molecular Docking, Molecular Dynamics, and SAR Studies. J. Tradit. Complement. Med. 2021;12:16\u201334. doi: 10.1016/j.jtcme.2021.05.001.", "ArticleIdList": ["10.1016/j.jtcme.2021.05.001", "PMC8126476", "34026584"]}, {"Citation": "Tuble S.C., Anwar J., Gale J.D. An Approach to Developing a Force Field for Molecular Simulation of Martensitic Phase Transitions between Phases with Subtle Differences in Energy and Structure. J. Am. Chem. Soc. 2004;126:396\u2013405. doi: 10.1021/ja0356131.", "ArticleIdList": ["10.1021/ja0356131", "14709107"]}, {"Citation": "Darden T., York D., Pedersen L. Particle mesh Ewald: An N\u22c5log(N) method for Ewald sums in large systems. J. Chem. Phys. 1993;98:10089\u201310092. doi: 10.1063/1.464397.", "ArticleIdList": ["10.1063/1.464397"]}, {"Citation": "Hess B., Bekker H., Berendsen H.J.C., Fraaije J.G.E.M. LINCS: A linear constraint solver for molecular simulations. J. Comput. Chem. 1997;18:1463\u20131472. doi: 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H.", "ArticleIdList": ["10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H"]}, {"Citation": "P\u00e1ll S., Hess B. A flexible algorithm for calculating pair interactions on SIMD architectures. Comput. Phys. Comm. 2013;184:2641\u20132650. doi: 10.1016/j.cpc.2013.06.003.", "ArticleIdList": ["10.1016/j.cpc.2013.06.003"]}, {"Citation": "Kumari R., Kumar R., Lynn A. g_mmpbsa\u2014A GROMACS Tool for High-Throughput MM-PBSA Calculations. J. Chem. Inf. Model. 2014;54:1951\u20131962. doi: 10.1021/ci500020m.", "ArticleIdList": ["10.1021/ci500020m", "24850022"]}, {"Citation": "Ganesan A. The impact of natural products upon modern drug discovery. Curr. Opin. Chem. Biol. 2008;12:306\u2013317. doi: 10.1016/j.cbpa.2008.03.016.", "ArticleIdList": ["10.1016/j.cbpa.2008.03.016", "18423384"]}, {"Citation": "Lipinski C.A. Chris Lipinski discusses life and chemistry after the Rule of Five. Drug Discov. Today. 2003;8:12\u201316.", "ArticleIdList": ["12546981"]}, {"Citation": "Leeson P.D., Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discov. 2007;6:881\u2013890. doi: 10.1038/nrd2445.", "ArticleIdList": ["10.1038/nrd2445", "17971784"]}, {"Citation": "Lipinski C.A. Lead- and drug-like compounds: The rule-of-five revolution. Drug Discov. Today Technol. 2004;1:337\u2013341. doi: 10.1016/j.ddtec.2004.11.007.", "ArticleIdList": ["10.1016/j.ddtec.2004.11.007", "24981612"]}, {"Citation": "Ioakimidis L., Thoukydidis L., Mirza A., Naeem S., Reynisson J. Benchmarking the Reliability of QikProp. Correlation between Experimental and Predicted Values. QSAR Comb. Sci. 2008;27:445\u2013456. doi: 10.1002/qsar.200730051.", "ArticleIdList": ["10.1002/qsar.200730051"]}, {"Citation": "Jorgensen W.L., Duffy E.M. Prediction of drug solubility from Monte Carlo simulations. Bioorg. Med. Chem. Lett. 2000;10:1155\u20131158. doi: 10.1016/S0960-894X(00)00172-4.", "ArticleIdList": ["10.1016/S0960-894X(00)00172-4", "10866370"]}, {"Citation": "Colmenarejo G., Alvarez-Pedraglio A., Lavandera J.-L. Cheminformatic Models To Predict Binding Affinities to Human Serum Albumin. J. Med. Chem. 2001;44:4370\u20134378. doi: 10.1021/jm010960b.", "ArticleIdList": ["10.1021/jm010960b", "11728183"]}, {"Citation": "Yazdanian M., Glynn S.L., Wright J.L., Hawi A. Correlating Partitioning and Caco-2 Cell Permeability of Structurally Diverse Small Molecular Weight Compounds. Pharm. Res. 1998;15:1490\u20131494. doi: 10.1023/A:1011930411574.", "ArticleIdList": ["10.1023/A:1011930411574", "9755906"]}, {"Citation": "Duffy E.M., Jorgensen W.L. Prediction of Properties from Simulations:\u2009 Free Energies of Solvation in Hexadecane, Octanol, and Water. J. Am. Chem. Soc. 2000;122:2878\u20132888. doi: 10.1021/ja993663t.", "ArticleIdList": ["10.1021/ja993663t"]}, {"Citation": "Irvine J.D., Takahashi L., Lockhart K., Cheong J., Tolan J.W., Selick H.E., Grove J.R. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J. Pharm. Sci. 1999;88:28\u201333. doi: 10.1021/js9803205.", "ArticleIdList": ["10.1021/js9803205", "9874698"]}, {"Citation": "Cavalli A., Poluzzi E., De Ponti F., Recanatini M. Toward a pharmacophore for drugs inducing the long QT syndrome: Insights from a CoMFA study of HERG K(+) channel blockers. J. Med. Chem. 2002;45:3844\u20133853. doi: 10.1021/jm0208875.", "ArticleIdList": ["10.1021/jm0208875", "12190308"]}, {"Citation": "Xie C.-L., Zhang D., Xia J.-M., Hu C.-C., Lin T., Lin Y.-K., Wang G.-H., Tian W.-J., Li Z.-P., Zhang X.-K., et al. Steroids from the Deep-Sea-Derived Fungus Penicillium granulatum MCCC 3A00475 Induced Apoptosis via Retinoid X Receptor (RXR)-\u03b1 Pathway. Mar. Drugs. 2019;17:178. doi: 10.3390/md17030178.", "ArticleIdList": ["10.3390/md17030178", "PMC6472029", "30893778"]}, {"Citation": "He F., Han Z., Peng J., Qian P.Y., Qi S.H. Antifouling indole alkaloids from two marine derived fungi. Nat. Prod. Commun. 2013;8:329\u2013332. doi: 10.1177/1934578X1300800313.", "ArticleIdList": ["10.1177/1934578X1300800313", "23678803"]}, {"Citation": "Holm L., Sander C. The FSSP database of structurally aligned protein fold families. Nucleic Acids Res. 1994;22:3600\u20133609.", "ArticleIdList": ["PMC308329", "7937067"]}, {"Citation": "Su X.D., Taddei N., Stefani M., Ramponi G., Nordlund P. The crystal structure of a low-molecular-weight phosphotyrosine protein phosphatase. Nature. 1994;370:575\u2013578. doi: 10.1038/370575a0.", "ArticleIdList": ["10.1038/370575a0", "8052313"]}, {"Citation": "Rudolph J. Cdc25 phosphatases: Structure, specificity, and mechanism. Biochemistry. 2007;46:3595\u20133604. doi: 10.1021/bi700026j.", "ArticleIdList": ["10.1021/bi700026j", "17328562"]}, {"Citation": "Denu J.M., Dixon J.E. A catalytic mechanism for the dual-specific phosphatases. Proc. Natl. Acad. Sci. USA. 1995;92:5910\u20135914. doi: 10.1073/pnas.92.13.5910.", "ArticleIdList": ["10.1073/pnas.92.13.5910", "PMC41611", "7597052"]}, {"Citation": "Borgne A., Meijer L. Sequential dephosphorylation of p34(cdc2) on Thr-14 and Tyr-15 at the prophase/metaphase transition. J. Biol. Chem. 1996;271:27847\u201327854. doi: 10.1074/jbc.271.44.27847.", "ArticleIdList": ["10.1074/jbc.271.44.27847", "8910383"]}, {"Citation": "Russo A.A., Jeffrey P.D., Pavletich N.P. Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat. Struct. Biol. 1996;3:696\u2013700. doi: 10.1038/nsb0896-696.", "ArticleIdList": ["10.1038/nsb0896-696", "8756328"]}, {"Citation": "McCain D.F., Catrina I.E., Hengge A.C., Zhang Z.Y. The catalytic mechanism of Cdc25A phosphatase. J. Biol. Chem. 2002;277:11190\u201311200. doi: 10.1074/jbc.M109636200.", "ArticleIdList": ["10.1074/jbc.M109636200", "11805096"]}, {"Citation": "Arantes G.M. Free-energy profiles for catalysis by dual-specificity phosphatases. Biochem. J. 2006;399:343\u2013350. doi: 10.1042/BJ20060637.", "ArticleIdList": ["10.1042/BJ20060637", "PMC1609924", "16784417"]}, {"Citation": "Xu R.X., Hassell A.M., Vanderwall D., Lambert M.H., Holmes W.D., Luther M.A., Rocque W.J., Milburn M.V., Zhao Y., Ke H., et al. Atomic structure of PDE4: Insights into phosphodiesterase mechanism and specificity. Science. 2000;288:1822\u20131825. doi: 10.1126/science.288.5472.1822.", "ArticleIdList": ["10.1126/science.288.5472.1822", "10846163"]}, {"Citation": "Kontoyianni M., McClellan L.M., Sokol G.S. Evaluation of Docking Performance:\u2009 Comparative Data on Docking Algorithms. J. Med. Chem. 2004;47:558\u2013565. doi: 10.1021/jm0302997.", "ArticleIdList": ["10.1021/jm0302997", "14736237"]}, {"Citation": "Albuquerque S.O., Barros T.G., Dias L.R.S., Lima C., Azevedo P., Flores-Junior L.A.P., Dos Santos E.G., Loponte H.F., Pinheiro S., Dias W.B., et al. Biological evaluation and molecular modeling of peptidomimetic compounds as inhibitors for O-GlcNAc transferase (OGT) Eur. J. Pharm. Sci. 2020;154:105510. doi: 10.1016/j.ejps.2020.105510.", "ArticleIdList": ["10.1016/j.ejps.2020.105510", "32801002"]}, {"Citation": "De Souza A.S., Pacheco B.D.C., Pinheiro S., Muri E.M.F., Dias L.R.S., Lima C.H.S., Garrett R., de Moraes M.B.M., de Souza B.E.G., Puzer L. 3-Acyltetramic acids as a novel class of inhibitors for human kallikreins 5 and 7. Bioorg. Med. Chem. Lett. 2019;29:1094\u20131098. doi: 10.1016/j.bmcl.2019.02.031.", "ArticleIdList": ["10.1016/j.bmcl.2019.02.031", "30833107"]}, {"Citation": "El-Naggar A.M., Hassan A.M.A., Elkaeed E.B., Alesawy M.S., Al-Karmalawy A.A. Design, synthesis, and SAR studies of novel 4-methoxyphenyl pyrazole and pyrimidine derivatives as potential dual tyrosine kinase inhibitors targeting both EGFR and VEGFR-2. Bioorg. Chem. 2022;123:105770. doi: 10.1016/j.bioorg.2022.105770.", "ArticleIdList": ["10.1016/j.bioorg.2022.105770", "35395446"]}, {"Citation": "Park H., Bahn Y.J., Jung S.K., Jeong D.G., Lee S.H., Seo I., Yoon T.S., Kim S.J., Ryu S.E. Discovery of novel Cdc25 phosphatase inhibitors with micromolar activity based on the structure-based virtual screening. J. Med. Chem. 2008;51:5533\u20135541. doi: 10.1021/jm701157g.", "ArticleIdList": ["10.1021/jm701157g", "18714978"]}, {"Citation": "Hwang-Seo P., Suk-Kyeong J., Young-Jae B., Seong Eon R., Seung-Jun K. Discovery of Novel and Potent Cdc25 Phosphatase Inhibitors Based on the Structure-Based De Novo Design. Bull. Korean Chem. Soc. 2009;30:1313\u20131316. doi: 10.5012/BKCS.2009.30.6.1313.", "ArticleIdList": ["10.5012/BKCS.2009.30.6.1313"]}, {"Citation": "Kabakci Z., K\u00e4ppeli S., Cant\u00f9 C., Jensen L.D., K\u00f6nig C., Toggweiler J., Gentili C., Ribaudo G., Zagotto G., Basler K., et al. Pharmacophore-guided discovery of CDC25 inhibitors causing cell cycle arrest and tumor regression. Sci. Rep. 2019;9:1335. doi: 10.1038/s41598-019-38579-7.", "ArticleIdList": ["10.1038/s41598-019-38579-7", "PMC6362118", "30718768"]}, {"Citation": "Barford D., Flint A.J., Tonks N.K. Crystal structure of human protein tyrosine phosphatase 1B. Science. 1994;263:1397\u20131404. doi: 10.1126/science.8128219.", "ArticleIdList": ["10.1126/science.8128219", "8128219"]}, {"Citation": "Zhang Z.Y. Protein-tyrosine phosphatases: Biological function, structural characteristics, and mechanism of catalysis. Crit. Rev. Biochem. Mol. Biol. 1998;33:1\u201352. doi: 10.1080/10409239891204161.", "ArticleIdList": ["10.1080/10409239891204161", "9543627"]}, {"Citation": "Brand\u00e3o T.A.S., Hengge A.C., Johnson S.J. Insights into the reaction of protein-tyrosine phosphatase 1B: Crystal structures for transition state analogs of both catalytic steps. J. Biol. Chem. 2010;285:15874\u201315883. doi: 10.1074/jbc.M109.066951.", "ArticleIdList": ["10.1074/jbc.M109.066951", "PMC2871455", "20236928"]}, {"Citation": "Shen K., Keng Y.F., Wu L., Guo X.L., Lawrence D.S., Zhang Z.Y. Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure. J. Biol. Chem. 2001;276:47311\u201347319. doi: 10.1074/jbc.M106568200.", "ArticleIdList": ["10.1074/jbc.M106568200", "11584002"]}, {"Citation": "Reddy M.V., Ghadiyaram C., Panigrahi S.K., Krishnamurthy N.R., Hosahalli S., Chandrasekharappa A.P., Manna D., Badiger S.E., Dubey P.K., Mangamoori L.N. X-ray structure of PTP1B in complex with a new PTP1B inhibitor. Protein Pept. Lett. 2014;21:90\u201393. doi: 10.2174/09298665113209990089.", "ArticleIdList": ["10.2174/09298665113209990089", "23964742"]}, {"Citation": "Sun Z., Liu Q., Qu G., Feng Y., Reetz M.T. Utility of B-Factors in Protein Science: Interpreting Rigidity, Flexibility, and Internal Motion and Engineering Thermostability. Chem. Rev. 2019;119:1626\u20131665. doi: 10.1021/acs.chemrev.8b00290.", "ArticleIdList": ["10.1021/acs.chemrev.8b00290", "30698416"]}, {"Citation": "Liu W.S., Wang R.R., Yue H., Zheng Z.H., Lu X.H., Wang S.Q., Dong W.L., Wang R.L. Design, synthesis, biological evaluation and molecular dynamics studies of 4-thiazolinone derivatives as protein tyrosine phosphatase 1B (PTP1B) inhibitors. J. Biomol. Struct. Dyn. 2020;38:3814\u20133824. doi: 10.1080/07391102.2019.1664333.", "ArticleIdList": ["10.1080/07391102.2019.1664333", "31490104"]}, {"Citation": "Mahapatra M.K., Bera K., Singh D.V., Kumar R., Kumar M. In silico modelling and molecular dynamics simulation studies of thiazolidine based PTP1B inhibitors. J. Biomol. Struct. Dyn. 2018;36:1195\u20131211. doi: 10.1080/07391102.2017.1317026.", "ArticleIdList": ["10.1080/07391102.2017.1317026", "28393626"]}, {"Citation": "Manasa B., Manandhar S., Hari G., Priya K., Kumar B.H., Pai K.S.R. Virtual structure-based docking, WaterMap, and molecular dynamics guided identification of the potential natural compounds as inhibitors of protein-tyrosine phosphatase 1B. J. Mol. Struct. 2021;1226:129396. doi: 10.1016/j.molstruc.2020.129396.", "ArticleIdList": ["10.1016/j.molstruc.2020.129396"]}, {"Citation": "Cai J., Zhao L., Tao W. Potent protein tyrosine phosphatase 1B (PTP1B) inhibiting constituents from Anoectochilus chapaensis and molecular docking studies. Pharm. Biol. 2015;53:1030\u20131034. doi: 10.3109/13880209.2014.957781.", "ArticleIdList": ["10.3109/13880209.2014.957781", "25609152"]}, {"Citation": "Peach M.L., Tan N., Choyke S.J., Giubellino A., Athauda G., Burke T.R., Jr., Nicklaus M.C., Bottaro D.P. Directed discovery of agents targeting the Met tyrosine kinase domain by virtual screening. J. Med. Chem. 2009;52:943\u2013951. doi: 10.1021/jm800791f.", "ArticleIdList": ["10.1021/jm800791f", "PMC2698034", "19199650"]}, {"Citation": "Cui J.J., Tran-Dub\u00e9 M., Shen H., Nambu M., Kung P.P., Pairish M., Jia L., Meng J., Funk L., Botrous I., et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK) J. Med. Chem. 2011;54:6342\u20136363. doi: 10.1021/jm2007613.", "ArticleIdList": ["10.1021/jm2007613", "21812414"]}, {"Citation": "Dong H.J., Li P., Wu C.L., Zhou X.Y., Lu H.J., Zhou T. Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations. Lung Cancer. 2016;102:118\u2013121. doi: 10.1016/j.lungcan.2016.11.006.", "ArticleIdList": ["10.1016/j.lungcan.2016.11.006", "27987579"]}, {"Citation": "Heist R.S., Sequist L.V., Borger D., Gainor J.F., Arellano R.S., Le L.P., Dias-Santagata D., Clark J.W., Engelman J.A., Shaw A.T., et al. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping. J. Thorac. Oncol. 2016;11:1242\u20131245. doi: 10.1016/j.jtho.2016.06.013.", "ArticleIdList": ["10.1016/j.jtho.2016.06.013", "27343442"]}, {"Citation": "Reungwetwattana T., Liang Y., Zhu V., Ou S.I. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable. Lung Cancer. 2017;103:27\u201337. doi: 10.1016/j.lungcan.2016.11.011.", "ArticleIdList": ["10.1016/j.lungcan.2016.11.011", "28024693"]}, {"Citation": "Kang J., Chen H.J., Wang Z., Liu J., Li B., Zhang T., Yang Z., Wu Y.L., Yang J.J. Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib. J. Thorac. Oncol. 2018;13:e49\u2013e53. doi: 10.1016/j.jtho.2017.10.028.", "ArticleIdList": ["10.1016/j.jtho.2017.10.028", "29128427"]}, {"Citation": "Parikh P.K., Ghate M.D. Recent advances in the discovery of small molecule c-Met Kinase inhibitors. Eur. J. Med. Chem. 2018;143:1103\u20131138. doi: 10.1016/j.ejmech.2017.08.044.", "ArticleIdList": ["10.1016/j.ejmech.2017.08.044", "29157685"]}, {"Citation": "Nishii H., Chiba T., Morikami K., Fukami T.A., Sakamoto H., Ko K., Koyano H. Discovery of 6-benzyloxyquinolines as c-Met selective kinase inhibitors. Bioorg. Med. Chem. Lett. 2010;20:1405\u20131409. doi: 10.1016/j.bmcl.2009.12.109.", "ArticleIdList": ["10.1016/j.bmcl.2009.12.109", "20093027"]}, {"Citation": "Ye L., Wu J., Yang J., Chen W., Luo Y., Zhang Y. Design, synthesis and molecular docking analysis of some novel 7-[(quinolin-6-yl)methyl] purines as potential c-Met inhibitors. Med. Chem. Res. 2015;24:3327\u20133333. doi: 10.1007/s00044-015-1383-z.", "ArticleIdList": ["10.1007/s00044-015-1383-z"]}, {"Citation": "Ye L., Ou X., Tian Y., Yu B., Luo Y., Feng B., Lin H., Zhang J., Wu S. Indazoles as potential c-Met inhibitors: Design, synthesis and molecular docking studies. Eur. J. Med. Chem. 2013;65:112\u2013118. doi: 10.1016/j.ejmech.2013.04.004.", "ArticleIdList": ["10.1016/j.ejmech.2013.04.004", "23702473"]}, {"Citation": "Cui H., Peng X., Liu J., Ma C., Ji Y., Zhang W., Geng M., Li Y. Design, synthesis and biological evaluation of c-Met kinase inhibitors bearing 2-oxo-1,2-dihydroquinoline scaffold. Bioorg. Med. Chem. Lett. 2016;26:4483\u20134486. doi: 10.1016/j.bmcl.2016.07.077.", "ArticleIdList": ["10.1016/j.bmcl.2016.07.077", "27524312"]}, {"Citation": "El-Wakil M.H., Ashour H.M., Saudi M.N., Hassan A.M., Labouta I.M. Design, synthesis and molecular modeling studies of new series of antitumor 1,2,4-triazines with potential c-Met kinase inhibitory activity. Bioorg. Chem. 2018;76:154\u2013165. doi: 10.1016/j.bioorg.2017.11.006.", "ArticleIdList": ["10.1016/j.bioorg.2017.11.006", "29175587"]}, {"Citation": "El-Wakil M.H., Teleb M. Transforming Type II to Type I c-Met kinase inhibitors via combined scaffold hopping and structure-guided synthesis of new series of 1,3,4-thiadiazolo[2,3-c]-1,2,4-triazin-4-one derivatives. Bioorg. Chem. 2021;116:105304. doi: 10.1016/j.bioorg.2021.105304.", "ArticleIdList": ["10.1016/j.bioorg.2021.105304", "34534756"]}, {"Citation": "Yuan H., Zhuang J., Hu S., Li H., Xu J., Hu Y., Xiong X., Chen Y., Lu T. Molecular modeling of exquisitely selective c-Met inhibitors through 3D-QSAR and molecular dynamics simulations. J. Chem. Inf. Model. 2014;54:2544\u20132554. doi: 10.1021/ci500268s.", "ArticleIdList": ["10.1021/ci500268s", "25181449"]}, {"Citation": "Balasubramanian P.K., Balupuri A., Bhujbal S.P., Cho S.J. 3D-QSAR-aided design of potent c-Met inhibitors using molecular dynamics simulation and binding free energy calculation. J. Biomol. Struct. Dyn. 2019;37:2165\u20132178. doi: 10.1080/07391102.2018.1479309.", "ArticleIdList": ["10.1080/07391102.2018.1479309", "30044205"]}, {"Citation": "Damghani T., Sedghamiz T., Sharifi S., Pirhadi S. Critical c-Met-inhibitor interactions resolved from molecular dynamics simulations of different c-Met complexes. J. Mol. Struct. 2020;1203:127456. doi: 10.1016/j.molstruc.2019.127456.", "ArticleIdList": ["10.1016/j.molstruc.2019.127456"]}, {"Citation": "Karplus M., Petsko G.A. Molecular dynamics simulations in biology. Nature. 1990;347:631\u2013639. doi: 10.1038/347631a0.", "ArticleIdList": ["10.1038/347631a0", "2215695"]}, {"Citation": "Gad M.M., Abdelwaly A., Helal M.A. Structural basis for the selectivity of 3rd generation EGFR inhibitors: A molecular dynamics study. J. Biomol. Struct. Dyn. 2022;29:1\u201311. doi: 10.1080/07391102.2022.2103028.", "ArticleIdList": ["10.1080/07391102.2022.2103028", "35903965"]}, {"Citation": "Soltan M.A., Eldeen M.A., Elbassiouny N., Kamel H.L., Abdelraheem K.M., El-Gayyed H.A., Gouda A.M., Sheha M.F., Fayad E., Ali O.A.A., et al. In Silico Designing of a Multitope Vaccine against Rhizopus microsporus with Potential Activity against Other Mucormycosis Causing Fungi. Cells. 2021;10:3014. doi: 10.3390/cells10113014.", "ArticleIdList": ["10.3390/cells10113014", "PMC8616407", "34831237"]}, {"Citation": "Arnittali M., Rissanou A.N., Harmandaris V. Structure Of Biomolecules Through Molecular Dynamics Simulations. Procedia Comput. Sci. 2019;156:69\u201378. doi: 10.1016/j.procs.2019.08.181.", "ArticleIdList": ["10.1016/j.procs.2019.08.181"]}, {"Citation": "Liu K., Watanabe E., Kokubo H. Exploring the stability of ligand binding modes to proteins by molecular dynamics simulations. J. Comput. Aided Mol. Des. 2017;31:201\u2013211. doi: 10.1007/s10822-016-0005-2.", "ArticleIdList": ["10.1007/s10822-016-0005-2", "28074360"]}, {"Citation": "Zhang X., Bhatt D., Zuckerman D.M. Automated sampling assessment for molecular simulations using the effective sample size. J. Chem. Theory Comput. 2010;6:3048\u20133057. doi: 10.1021/ct1002384.", "ArticleIdList": ["10.1021/ct1002384", "PMC3017371", "21221418"]}, {"Citation": "Manandhar A., Blass B.E., Colussi D.J., Almi I., Abou-Gharbia M., Klein M.L., Elokely K.M. Targeting SARS-CoV-2 M3CLpro by HCV NS3/4a Inhibitors: In Silico Modeling and In Vitro Screening. J. Chem. Inf. Model. 2021;61:1020\u20131032. doi: 10.1021/acs.jcim.0c01457.", "ArticleIdList": ["10.1021/acs.jcim.0c01457", "33538596"]}, {"Citation": "Almalki A.J., Ibrahim T.S., Elhady S.S., Hegazy W.A.H., Darwish K.M. Computational and Biological Evaluation of &beta;-Adrenoreceptor Blockers as Promising Bacterial Anti-Virulence Agents. Pharmaceuticals. 2022;15:110. doi: 10.3390/ph15020110.", "ArticleIdList": ["10.3390/ph15020110", "PMC8877484", "35215223"]}, {"Citation": "Benson N.C., Daggett V. A comparison of multiscale methods for the analysis of molecular dynamics simulations. J. Phys. Chem. B. 2012;116:8722\u20138731. doi: 10.1021/jp302103t.", "ArticleIdList": ["10.1021/jp302103t", "PMC3406285", "22494262"]}, {"Citation": "Helal M.A., Chittiboyina A.G., Avery M.A. New insights into the binding mode of melanin concentrating hormone receptor-1 antagonists: Homology modeling and explicit membrane molecular dynamics simulation study. J. Chem. Inf. Model. 2011;51:635\u2013646. doi: 10.1021/ci100355c.", "ArticleIdList": ["10.1021/ci100355c", "PMC3090266", "21370821"]}, {"Citation": "Yuvaniyama J., Denu J.M., Dixon J.E., Saper M.A. Crystal structure of the dual specificity protein phosphatase VHR. Science. 1996;272:1328\u20131331. doi: 10.1126/science.272.5266.1328.", "ArticleIdList": ["10.1126/science.272.5266.1328", "8650541"]}, {"Citation": "Gliubich F., Gazerro M., Zanotti G., Delbono S., Bombieri G., Berni R. Active site structural features for chemically modified forms of rhodanese. J. Biol. Chem. 1996;271:21054\u201321061. doi: 10.1074/jbc.271.35.21054.", "ArticleIdList": ["10.1074/jbc.271.35.21054", "8702871"]}, {"Citation": "Zhang M., Van Etten R.L., Stauffacher C.V. Crystal structure of bovine heart phosphotyrosyl phosphatase at 2.2-A resolution. Biochemistry. 1994;33:11097\u201311105. doi: 10.1021/bi00203a006.", "ArticleIdList": ["10.1021/bi00203a006", "7537084"]}, {"Citation": "Cavasotto C.N. Binding Free Energy Calculation Using Quantum Mechanics Aimed for Drug Lead Optimization. Methods Mol. Biol. 2020;2114:257\u2013268. doi: 10.1007/978-1-0716-0282-9_16.", "ArticleIdList": ["10.1007/978-1-0716-0282-9_16", "32016898"]}, {"Citation": "Singh W., Karabencheva-Christova T.G., Black G.W., Ainsley J., Dover L., Christov C.Z. Conformational Dynamics, Ligand Binding and Effects of Mutations in NirE an S-Adenosyl-L-Methionine Dependent Methyltransferase. Sci. Rep. 2016;6:20107. doi: 10.1038/srep20107.", "ArticleIdList": ["10.1038/srep20107", "PMC4731766", "26822701"]}, {"Citation": "Fatriansyah J.F., Rizqillah R.K., Yandi M.Y., Fadilah, Sahlan M. Molecular docking and dynamics studies on propolis sulabiroin-A as a potential inhibitor of SARS-CoV-2. J. King Saud Univ. Sci. 2022;34:101707. doi: 10.1016/j.jksus.2021.101707.", "ArticleIdList": ["10.1016/j.jksus.2021.101707", "PMC8591974", "34803333"]}, {"Citation": "Sun J.P., Fedorov A.A., Lee S.Y., Guo X.L., Shen K., Lawrence D.S., Almo S.C., Zhang Z.Y. Crystal structure of PTP1B complexed with a potent and selective bidentate inhibitor. J. Biol. Chem. 2003;278:12406\u201312414. doi: 10.1074/jbc.M212491200.", "ArticleIdList": ["10.1074/jbc.M212491200", "12547827"]}, {"Citation": "Scapin G., Patel S.B., Becker J.W., Wang Q., Desponts C., Waddleton D., Skorey K., Cromlish W., Bayly C., Therien M., et al. The structural basis for the selectivity of benzotriazole inhibitors of PTP1B. Biochemistry. 2003;42:11451\u201311459. doi: 10.1021/bi035098j.", "ArticleIdList": ["10.1021/bi035098j", "14516196"]}, {"Citation": "Zhao H., Liu G., Xin Z., Serby M.D., Pei Z., Szczepankiewicz B.G., Hajduk P.J., Abad-Zapatero C., Hutchins C.W., Lubben T.H., et al. Isoxazole carboxylic acids as protein tyrosine phosphatase 1B (PTP1B) inhibitors. Bioorg. Med. Chem. Lett. 2004;14:5543\u20135546. doi: 10.1016/j.bmcl.2004.08.063.", "ArticleIdList": ["10.1016/j.bmcl.2004.08.063", "15482920"]}, {"Citation": "Eathiraj S., Palma R., Volckova E., Hirschi M., France D.S., Ashwell M.A., Chan T.C. Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J. Biol. Chem. 2011;286:20666\u201320676. doi: 10.1074/jbc.M110.213801.", "ArticleIdList": ["10.1074/jbc.M110.213801", "PMC3121448", "21454604"]}, {"Citation": "Kufareva I., Abagyan R. Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states. J. Med. Chem. 2008;51:7921\u20137932. doi: 10.1021/jm8010299.", "ArticleIdList": ["10.1021/jm8010299", "PMC2669721", "19053777"]}, {"Citation": "Albrecht B.K., Harmange J.C., Bauer D., Berry L., Bode C., Boezio A.A., Chen A., Choquette D., Dussault I., Fridrich C., et al. Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase. J. Med. Chem. 2008;51:2879\u20132882. doi: 10.1021/jm800043g.", "ArticleIdList": ["10.1021/jm800043g", "18426196"]}, {"Citation": "Bellon S.F., Kaplan-Lefko P., Yang Y., Zhang Y., Moriguchi J., Rex K., Johnson C.W., Rose P.E., Long A.M., O\u2019Connor A.B., et al. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J. Biol. Chem. 2008;283:2675\u20132683. doi: 10.1074/jbc.M705774200.", "ArticleIdList": ["10.1074/jbc.M705774200", "18055465"]}, {"Citation": "Johnson L.N., Noble M.E., Owen D.J. Active and inactive protein kinases: Structural basis for regulation. Cell. 1996;85:149\u2013158. doi: 10.1016/S0092-8674(00)81092-2.", "ArticleIdList": ["10.1016/S0092-8674(00)81092-2", "8612268"]}, {"Citation": "Kornev A.P., Haste N.M., Taylor S.S., Eyck L.F. Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc. Natl. Acad. Sci. USA. 2006;103:17783\u201317788. doi: 10.1073/pnas.0607656103.", "ArticleIdList": ["10.1073/pnas.0607656103", "PMC1693824", "17095602"]}, {"Citation": "Cheng S., Niv M.Y. Molecular Dynamics Simulations and Elastic Network Analysis of Protein Kinase B (Akt/PKB) Inactivation. J. Chem. Inf. Model. 2010;50:1602\u20131610. doi: 10.1021/ci100076j.", "ArticleIdList": ["10.1021/ci100076j", "20735046"]}, {"Citation": "Elmaaty A.A., Darwish K.M., Chrouda A., Boseila A.A., Tantawy M.A., Elhady S.S., Shaik A.B., Mustafa M., Al-karmalawy A.A. In Silico and In Vitro Studies for Benzimidazole Anthelmintics Repurposing as VEGFR-2 Antagonists: Novel Mebendazole-Loaded Mixed Micelles with Enhanced Dissolution and Anticancer Activity. ACS Omega. 2022;7:875\u2013899. doi: 10.1021/acsomega.1c05519.", "ArticleIdList": ["10.1021/acsomega.1c05519", "PMC8757357", "35036753"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "12", "Day": "10"}, {"Year": "2023", "Month": "1", "Day": "13"}, {"Year": "2023", "Month": "1", "Day": "19"}, {"Year": "2023", "Month": "2", "Day": "25", "Hour": "3", "Minute": "38"}, {"Year": "2023", "Month": "2", "Day": "26", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "2", "Day": "26", "Hour": "6", "Minute": "1"}, {"Year": "2023", "Month": "1", "Day": "21"}], "PublicationStatus": "epublish", "ArticleIdList": ["36837781", "PMC9964656", "10.3390/metabo13020162", "metabo13020162"]}}], "PubmedBookArticle": []}